MedTrace Logo

Phase 1 Safety Study of ALRN-5281 in Healthy Subjects

NCT01775358 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2013-05-30

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the safety and tolerability of a single dose of ALRN-5281 administered by subcutaneous injection to healthy adult volunteers.

Conditions

  • Growth Hormone Deficiency

Interventions

DRUG

ALRN-5281 0.015 mg/kg

DRUG

ALRN-5281 0.05 mg/kg

DRUG

ALRN-5281 0.15 mg/kg

DRUG

Placebo 0.015 mg/kg

DRUG

Placebo 0.05mg/kg

DRUG

Placebo 0.15mg/kg

Sponsors & Collaborators

  • Aileron Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Bradley D Vince, D.O. · Vince and Associates

  • Hubert C Chen, M.D. · Aileron Therapeutics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2013-05-31
Completion
2013-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01775358 on ClinicalTrials.gov